Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Thursday,Benzinga reports. They currently have a $207.00 price target on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also issued reports on JAZZ. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Royal Bank of Canada raised their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $125.10 on Thursday. The company’s 50 day simple moving average is $113.29 and its two-hundred day simple moving average is $110.62. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $134.17. The stock has a market capitalization of $7.56 billion, a PE ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57.

Insider Buying and Selling

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock worth $720,160 in the last ninety days. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Jazz Pharmaceuticals in the second quarter worth $29,000. EverSource Wealth Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth $33,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.